1Program in Molecular Pharmacology; 2Human Oncology and Pathogenesis Program; 3Program in Cell Biology, Memorial Sloan-Kettering Cancer Center; 4Weill Cornell Medical College, New York, New York; and 5Bayer HealthCare, Global Drug Discovery, Berlin, Germany.
Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16.
The effects of selective phosphoinositide 3-kinase (PI3K) and AKT inhibitors were compared in human tumor cell lines in which the pathway is dysregulated. Both caused inhibition of AKT, relief of feedback inhibition of receptor tyrosine kinases, and growth arrest. However, only the PI3K inhibitors caused rapid induction of cell death. In seeking a mechanism for this phenomenon, we found that PI3K inhibition, but not AKT inhibition, causes rapid inhibition of wild-type RAS and of RAF-MEK-ERK signaling. Inhibition of RAS-ERK signaling is transient, rebounding a few hours after drug addition, and is required for rapid induction of apoptosis. Combined MEK and AKT inhibition also promotes cell death, and in murine models of HER2(+) cancer, either pulsatile PI3K inhibition or combined MEK and AKT inhibition causes tumor regression. We conclude that PI3K is upstream of RAS and AKT and that pulsatile inhibition of both pathways is sufficient for effective antitumor activity.
在通路失调的人类肿瘤细胞系中比较了选择性磷酸肌醇 3-激酶 (PI3K) 和 AKT 抑制剂的作用。两者均导致 AKT 抑制、受体酪氨酸激酶的反馈抑制缓解和生长停滞。然而,只有 PI3K 抑制剂会导致细胞死亡的快速诱导。在寻求这种现象的机制时,我们发现 PI3K 抑制而不是 AKT 抑制会导致野生型 RAS 和 RAF-MEK-ERK 信号的快速抑制。RAS-ERK 信号的抑制是短暂的,在药物添加后几个小时内反弹,并且是快速诱导细胞凋亡所必需的。MEK 和 AKT 的联合抑制也会促进细胞死亡,并且在 HER2(+)癌症的小鼠模型中,脉冲式 PI3K 抑制或 MEK 和 AKT 的联合抑制均可引起肿瘤消退。我们得出结论,PI3K 位于 RAS 和 AKT 的上游,两条通路的脉冲式抑制足以发挥有效的抗肿瘤活性。